Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2015

View Archived Issues

Edge Therapeutics reports data from phase I/II of EG-1962

Alzheimer's Drug Discovery Foundation joins up with Pfizer's Centers for Therapeutic Innovation

Advaxis and Incyte to evaluate combination of two novel cancer immunotherapies

Voyager Therapeutics and Genzyme to develop novel AAV gene therapies for CNS disorders

First clinical study of Niagen meets primary endpoint

ViveBio signs licensing agreement with Renovar for urine-based biomarkers for kidney disease

Plant-produced decoy shows potential against MERS-CoV

First vaccine that shows efficacy against CCHF virus in mice

Taisho Pharmaceutical divulges GlyT-1 inhibitors

Novo Nordkisk reports development of anti-uPA MAbs

Bayer Schering Pharma discloses GnRH receptor antagonists

Roche and Genentech patent describes new PAK 1 inhibitors

The University of Colorado discloses new organosilicon anticancer agents

Affinivax collaborates with PATH to advance vaccine candidate for Pneumococcal disease

Alzheimer's Association, Weston Brain Institute and Alzheimer's Research UK join forces

First clinical study of ONS-3010 meets primary endpoints

Compugen presents data supporting potential of CGEN-15049 as target for cancer immunotherapy

Janssen launches three new research platforms

MonoSol Rx presents pipeline update

Amyloid light-chain amyloidosis treatments receive FDA orphan drug status

FDA grants orphan drug status to VS-5584 for malignant mesothelioma

IOmet Pharma discloses preclinical results for tryptophan metabolism modulators for cancer

Phase I study reveals promise of ACE-910 in hemophilia

Health Canada updates Zelboraf labeling to advise of pancreatitis risk

Repurposed maprotiline shows antibiofilm activity against Francisella

Novo Nordisk and Merck & Co. join GPCR Consortium

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...